Literature DB >> 23516678

Disease burden of chronic hepatitis B among immigrants in Canada.

William W L Wong, Gloria Woo, E Jenny Heathcote, Murray Krahn.   

Abstract

BACKGROUND: The prevalence of chronic hepatitis B (CHB) infection among immigrants to North America ranges from 2% to 15%, 40% of whom develop advanced liver disease. Screening for hepatitis B surface antigen is not recommended for immigrants.
OBJECTIVE: To estimate the disease burden of CHB among immigrants in Canada using Markov cohort models comparing a cohort of immigrants with CHB versus a control cohort of immigrants without CHB.
METHODS: Markov cohort models were used to estimate life years, quality-adjusted life years and lifetime direct medical costs (adjusted to 2008 Canadian dollars) for a cohort of immigrants with CHB living in Canada in 2006, and an age-matched control cohort of immigrants without CHB living in Canada in 2006. Parameter values were derived from the published literature.
RESULTS: At the baseline estimate, the model suggested that the cohort of immigrants with CHB lost an average of 4.6 life years (corresponding to 1.5 quality-adjusted life years), had an increased average of $24,249 for lifetime direct medical costs, and had a higher lifetime risk for decompensated cirrhosis (12%), hepatocellular carcinoma (16%) and need for liver transplant (5%) when compared with the control cohort. DISCUSSION: Results of the present study showed that the socio-economic burden of CHB among immigrants living in Canada is substantial. Governments and health systems need to develop policies that promote early recognition of CHB and raise public awareness regarding hepatitis B to extend the lives of infected immigrants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23516678      PMCID: PMC3732151          DOI: 10.1155/2013/924640

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  49 in total

1.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

2.  Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

Authors:  Fasiha Kanwal; Mary Farid; Paul Martin; Gary Chen; Ian M Gralnek; Gareth S Dulai; Brennan M R Spiegel
Journal:  Am J Gastroenterol       Date:  2006-09       Impact factor: 10.864

3.  Barriers to treatment of hepatitis B in an urban Chinatown community.

Authors:  Miguel Malespin; Shirley Wong; Fabiolla Siqueira; Brian Luc; Benjamin Ravaee; Charles Vainder; Scott J Cotler
Journal:  J Clin Gastroenterol       Date:  2012-09       Impact factor: 3.062

Review 4.  Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.

Authors:  C-M Chu; Y-F Liaw
Journal:  J Viral Hepat       Date:  2007-03       Impact factor: 3.728

5.  Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection.

Authors:  Yves M Gagnon; Adrian R Levy; Uchenna H Iloeje; Andrew H Briggs
Journal:  J Clin Gastroenterol       Date:  2004 Nov-Dec       Impact factor: 3.062

6.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

7.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

Authors:  Uchenna H Iloeje; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Chien-Jen Chen
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

8.  Management of chronic hepatitis B: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

9.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

Authors:  Ting-Tsung Chang; Robert G Gish; Robert de Man; Adrian Gadano; José Sollano; You-Chen Chao; Anna S Lok; Kwang-Hyub Han; Zachary Goodman; Jin Zhu; Anne Cross; Deborah DeHertogh; Richard Wilber; Richard Colonno; David Apelian
Journal:  N Engl J Med       Date:  2006-03-09       Impact factor: 91.245

10.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Authors:  Ching-Lung Lai; Daniel Shouval; Anna S Lok; Ting-Tsung Chang; Hugo Cheinquer; Zachary Goodman; Deborah DeHertogh; Richard Wilber; Richard C Zink; Anne Cross; Richard Colonno; Lori Fernandes
Journal:  N Engl J Med       Date:  2006-03-09       Impact factor: 91.245

View more
  11 in total

1.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

2.  Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013.

Authors:  Yuan-Sheng Chen; Hui Zheng; Yan-Min Liu; Fu-Zhen Wang; Zhen-Hua Wu; Ning Miao; Xiao-Jin Sun; Guo-Min Zhang; Fu-Qiang Cui; Xiao-Feng Liang
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

3.  Let's Talk About B: Barriers to Hepatitis B Screening and Vaccination Among Asian and South Asian Immigrants in British Columbia.

Authors:  Lindsay Zibrik; Alan Huang; Vivian Wong; Helen Novak Lauscher; Queenie Choo; Eric M Yoshida; Kendall Ho
Journal:  J Racial Ethn Health Disparities       Date:  2018-03-19

4.  Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network.

Authors:  Carla S Coffin; Alnoor Ramji; Curtis L Cooper; David Miles; Karen E Doucette; Philip Wong; Edward Tam; David K Wong; Alexander Wong; Sylvester Ukabam; Robert J Bailey; Keith Tsoi; Brian Conway; Lisa Barrett; Tomasz I Michalak; Stephen E Congly; Gerald Minuk; Kelly Kaita; Erin Kelly; Hin Hin Ko; Harry L A Janssen; Julia Uhanova; Brendan C Lethebe; Sarah Haylock-Jacobs; Mang M Ma; Carla Osiowy; Scott K Fung
Journal:  CMAJ Open       Date:  2019-10-22

5.  Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Authors:  Carla S Coffin; Scott K Fung; Fernando Alvarez; Curtis L Cooper; Karen E Doucette; Claire Fournier; Erin Kelly; Hin Hin Ko; Mang M Ma; Steven R Martin; Carla Osiowy; Alnoor Ramji; Edward Tam; Jean Pierre Villeneuve
Journal:  Can Liver J       Date:  2018-12-25

6.  Seroprevalence of hepatitis B in previously undiagnosed patients: A community screening study.

Authors:  Daljeet Chahal; Joseph Gh Lee; Eric M Yoshida; Chris Lowe; Francis Ho; Vivian Sum; Peter Kwan
Journal:  Can Liver J       Date:  2022-05-09

7.  The mean attributable health care costs associated with hepatitis B virus in Ontario, Canada: A matched cohort study.

Authors:  Natasha Nanwa; Jeffrey C Kwong; Jordan J Feld; C Fangyun Wu; Beate Sander
Journal:  Can Liver J       Date:  2022-08-16

Review 8.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

9.  Characterization of Acute and Chronic Hepatitis B Virus Genotypes in Canada.

Authors:  Carla Osiowy; Elizabeth Giles; Max Trubnikov; Yogesh Choudhri; Anton Andonov
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

10.  Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey.

Authors:  Guvenc Kockaya; Akin Kose; Fatma Betul Yenilmez; Oktay Ozdemir; Ece Kucuksayrac
Journal:  Cost Eff Resour Alloc       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.